Pfizer, Inc. (NYSE:PFE) – SunTrust Banks increased their FY2017 earnings per share (EPS) estimates for Pfizer in a research note issued to investors on Thursday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will earn $2.60 per share for the year, up from their prior estimate of $2.57. SunTrust Banks also issued estimates for Pfizer’s Q4 2017 earnings at $0.56 EPS, FY2018 earnings at $2.74 EPS and FY2019 earnings at $2.75 EPS.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The business’s revenue was up .9% on a year-over-year basis. During the same period last year, the firm posted $0.61 earnings per share.
WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/06/pfizer-inc-to-post-fy2017-earnings-of-2-60-per-share-suntrust-banks-forecasts-pfe.html.
A number of other analysts have also recently weighed in on PFE. UBS AG restated a “buy” rating and set a $38.00 target price on shares of Pfizer in a report on Monday, July 31st. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. BMO Capital Markets restated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research report on Wednesday, September 6th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company. Pfizer has an average rating of “Hold” and an average price target of $38.35.
Pfizer (NYSE PFE) opened at $35.55 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.34 and a debt-to-equity ratio of 0.58. The stock has a market cap of $211,428.25, a P/E ratio of 14.22, a PEG ratio of 2.46 and a beta of 1.01. Pfizer has a 1-year low of $29.90 and a 1-year high of $36.78.
A number of hedge funds have recently made changes to their positions in the stock. Northstar Group Inc. lifted its holdings in Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 35 shares during the last quarter. Peregrine Asset Advisers Inc. raised its stake in shares of Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC raised its stake in shares of Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the last quarter. River Wealth Advisors LLC raised its stake in shares of Pfizer by 0.3% in the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares during the last quarter. Finally, Meridian Wealth Management LLC raised its stake in shares of Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after acquiring an additional 57 shares during the last quarter. 69.01% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold a total of 374,621 shares of company stock worth $12,796,098 over the last 90 days. Company insiders own 0.06% of the company’s stock.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.60%. Pfizer’s dividend payout ratio is 79.01%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.